PF.02341066 serves as a multi-target inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and MET proto-oncogene receptor tyrosine kinase, and is the first agent approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of advanced ROS1 fusion-positive lung cancer (77, 78). This evidence concerns the gene MET and lung carcinoma.